Victory Capital Management Inc. Has $10.84 Million Stake in Disc Medicine, Inc. (NASDAQ:IRON)

Victory Capital Management Inc. raised its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 36.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 187,580 shares of the company’s stock after acquiring an additional 50,057 shares during the quarter. Victory Capital Management Inc.’s holdings in Disc Medicine were worth $10,835,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Profund Advisors LLC acquired a new stake in shares of Disc Medicine during the 3rd quarter valued at $496,000. Adage Capital Partners GP L.L.C. increased its position in Disc Medicine by 12.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,308,405 shares of the company’s stock valued at $61,469,000 after acquiring an additional 145,781 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Disc Medicine by 18.9% during the third quarter. Vanguard Group Inc. now owns 665,452 shares of the company’s stock worth $31,263,000 after purchasing an additional 105,685 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Disc Medicine by 309.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 84,200 shares of the company’s stock worth $3,956,000 after purchasing an additional 63,644 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Disc Medicine in the third quarter valued at $1,973,000. 83.70% of the stock is owned by institutional investors.

Disc Medicine Stock Performance

Disc Medicine stock opened at $30.36 on Monday. The stock has a market cap of $732.89 million, a PE ratio of -8.98 and a beta of 0.44. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The firm’s 50-day simple moving average is $43.53 and its 200 day simple moving average is $53.61.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). As a group, analysts predict that Disc Medicine, Inc. will post -4.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IRON. Wedbush reissued an “outperform” rating and issued a $43.00 price target (down previously from $84.00) on shares of Disc Medicine in a research note on Monday, April 1st. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Disc Medicine in a report on Friday. Morgan Stanley reduced their price objective on shares of Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Raymond James lifted their target price on shares of Disc Medicine from $40.00 to $43.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, BMO Capital Markets decreased their price target on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, April 2nd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Disc Medicine currently has a consensus rating of “Moderate Buy” and an average target price of $57.71.

Insider Activity

In related news, Director William Richard White sold 2,560 shares of the business’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $31.80, for a total value of $81,408.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.71% of the company’s stock.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.